Items Tagged ‘nhl’

June 8th, 2016

Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in Follicular Lymphoma

By

Genentech, announced positive results from the pivotal Phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin’s lymphoma (iNHL). The study compared Gazyva® (obinutuzumab) plus chemotherapy (CHOP, CVP or bendamustine) followed by Gazyva alone, head-to-head with Rituxan® (rituximab) plus chemotherapy followed by Rituxan alone. Results from […]

View full entry

Tags: Follicular Lymphoma, GALLIUM study, Gazyva, iNHL, News, nhl, Non-Hodgkin's Lymphoma, non-Hodgkin’s, rituxan, rituximab


December 17th, 2014

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment

By

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft function due to their need for HIV medications. Results from the clinical trial, presented at the American Society of Hematology […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Follicular Lymphoma, General HIV Related Cancers, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, hiv, hiv cancer, HIV Related Cancers, Indolent/Low Grade Non-Hodgkin's Lymphoma, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, nhl


September 4th, 2014

Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL

By

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma (NHL) can overcome the negative prognostic effect of the non–germinal B-cell phenotype in diffuse large B-cell lymphoma which is associated with significantly worse outcomes with […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Lymphoma, News, nhl, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, revlimid


September 3rd, 2014

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Reported to be Effective in Aggressive Non-Hodgkin’s Lymphoma at the National Cancer Institute (NCI)

By

SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin’s lymphoma with an anti-CD19 chimeric […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, anti-CD19, dlbcl, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, News, nhl, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, T cell therapy


May 28th, 2014

Lenalidomide Added to R-CHOP21 Therapy Shows High Response in Elderly, Untreated Large B-Cell Lymphoma Patients

By

Researchers reported in the journal The Lancet Oncology that the addition of lenalidomide to the standard R-CHOP21 regimen elicited a high response rate in elderly patients with untreated diffuse large B-cell lymphoma. In addition, the combination therapy was deemed to be safe in this population. Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, b-cell lymphoma, dlbcl, Follicular Lymphoma, Lymphoma, News, nhl, Non-Hodgkin's Lymphoma